Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

Menarini Biomarkers Singapore

Menarini Biomarkers Singapore

Menarini Biomarkers Singapore (MBS) was created in 2014 by Menarini Asia-Pacific and is fully owned by the Menarini Group. Its mission is to identify, develop and validate new biomarkers on circulating human cells for applications in diagnostics.

Many novel biomarkers will be identified using single cell analysis in the coming years. These discoveries will drive precision medicine, the new frontier in disease prediction and disease control. From liquid biopsies, circulating cells such as CFC (circulating fetal cells), CTC (circulating tumor cells) and PIC (pathogenic immune cells) will be captured by specific antibodies developed against novel targets, conjugated to FerroFluid (CELLSEARCH® technology) and further selected and analysed using the DEPArray platform.

Together with Menarini Silicon Biosystems (MSB), MBS aims to recover and select the rarest cell types from any type of tissues or liquid biopsies. The identified novel biomarkers will provide new tools and actionable insights for clinicians to track disease progression and measure real-time responses to therapies.